Carregant...
A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study
Bictegravir (BIC), a newly FDA-approved integrase strand transfer inhibitor (INSTI), as a single tablet regimen has proven efficacious in treating HIV-1 and SIV viruses, with reduced resistance. BIC clinical trials have not investigated its prophylaxis potency. This study investigates the HIV preven...
Guardat en:
| Publicat a: | Antiviral Res |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7263829/ https://ncbi.nlm.nih.gov/pubmed/30991088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2019.04.007 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|